Companion Dignostics: FDA Required Expressions for Targeted Therapies
Studied by 0 people
Call with Kai
Learn
Practice Test
Spaced Repetition
Match
Flashcards
Knowt Play1/40
Earn XP
Description and Tags
Name | Mastery | Learn | Test | Matching | Spaced | Call with Kai |
|---|
No analytics yet
Send a link to your students to track their progress
41 Terms
Erlotinib
EGFR exon 19 deletion or exon 21 L858R substitution
Cetuximab
EGFR, KRAS (non-mutated, wild type), BRAF V600E
Panitumumab
KRAS (non mutated; wild type)
Afatinib
EGFR
Gefitinib
EGFR exon 19 deletion or exon 21 L858R substitution
Dacomitinib
EGFR exon 19 deletion or exon 21 L858R substitution
Osimertinib
EGFR exon 19 deletion or exon 21 L858R substitution
EGFR T790M
Imatinib
BCR-ABL
C-kit
Dasatinib
BCR-ABL
Nilotinib
BCR-ABL
Ponatinib
BCR-ABL
T315l
Trastuzumab
HER2-neu
Pertuzumab
HER2-neu
Lapatinib
HER2-neu
Neratinib
HER2-neu
Trastuzumab-emtansine
HER2-neu
Tucatinib
HER2-neu
Trastuzumab deruxtecan
HER2-neu
Pembrolizumab
PD-L1
Cemiplimab
PD-L1 & SCLC
Atezolizumab
PD-L1
Olaparib
BRCA
Rucaparib
BRCA
Niraparib
BRCA
Trametinib-dabrafenib
BRAF
Alectinib
ALK
Ceritinib
ALK
Crizotinib
ALK
Brigatinib
ALK
Erlotinib
EGFR
Crizotinib
ALK
Vemurafenib
BRAF
Encorafenib
BRAF
Ivosidenib
IDH1
Capmatinib
MET exon 14 skipping
Alpelisib
PIK3CA
Larotrectinib
NTRK
Gilteritinib
FLT3
Midostaurin
FLT3
Lumakras
KRAS G12C mutation
Tazemetostat
EZH2
Note 
Flashcards (102)